miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53
Journal of Personalized Medicine · 25.08.2023 · 13 (9) · 1302
DOI: 10.3390/jpm13091302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 25.08.2023. Verfasst von Kyung-Jun Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute, Hallym University.
Abstract (Originalsprache)
(1)
Background
To examine miR-429-meditated DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 (DDX53) function in endometrial cancer (EC). (2)
Methods
DDX53 and miR-429 levels were measured using quantitative real-time polymerase chain reaction and western blotting assays, cell invasion and migration using Transwell invasion and wound healing assays, and cell proliferation using colony-forming/proliferation assays. A murine xenograft model was also generated to examine miR-429 and DDX53 functions in vivo. (3)
Results
DDX53 overexpression (OE) promoted key cancer phenotypes (proliferation, migration, and invasion) in EC, while in vivo, DDX53 OE hindered tumor growth in the murine xenograft model. Moreover, miR-429 was identified as a novel miRNA-targeting DDX53, which suppressed EC proliferation and invasion. (4)
Conclusions
DDX53 and miR-429 regulatory mechanisms could provide novel molecular therapies for EC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea.
- Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
- Departments of Anesthesiology and Pain Medicine, Chuncheon Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea.
- Department of Obstetrics and Gynecology, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
- Department of Obstetrics and Gynecology, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Kyeonggido 18450, Republic of Korea.
ORCID-Profile: Hyeong Su Kim, Hye-Yon Cho, Sung Taek Park
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute
- Hallym University
- Ministry of Science and ICT (MSIT)
- Ministry of Health and Welfare
Zitieren
APA
Lee, K. J., Singh, N., Bizuneh, M., Kim, N. H., Kim, H. S., Kim, Y., Lee, J. J., Kim, J. H., Kim, J., Jeong, S. Y., Cho, H. Y., & Park, S. T. (2023). miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine, 13(9), 1302. https://doi.org/10.3390/jpm13091302
Vancouver
Lee KJ, Singh N, Bizuneh M, Kim NH, Kim HS, Kim Y, et al. miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine. 2023;13(9):1302. doi:10.3390/jpm13091302
BibTeX
@article{Lee2023,
author = {Lee, Kyung-Jun and Singh, Nitya and Bizuneh, Michael and Kim, Nam-Hyeok and Kim, Hyeong Su and Kim, Youngmi and Lee, Jae-Jun and Kim, Jung Han and Kim, Jiye and Jeong, Soo Young and Cho, Hye-Yon and Park, Sung Taek},
title = {miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {9},
pages = {1302},
doi = {10.3390/jpm13091302}
}
EUVIMED